Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Regulatory News (AGY)

Share Price Information for Allergy Thera. (AGY)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
8.00
Ask:
9.00
Spread: 1.00 (12.50%)
Market Cap: £538.27m
AGY Live PriceLast checked at - London Stock Exchange

Intraday Allergy Thera. Share Chart

Director/PDMR Shareholding

4 Oct 2010 09:45

RNS Number : 7863T
Allergy Therapeutics PLC
04 October 2010
 



Allergy Therapeutics PLC

4 October 2010

 



Monday 4 October 2010

 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

 

Major Shareholdings/Holding by Director

 

 

Allergy Therapeutics plc (AIM: AGY), the fully integrated specialty pharmaceutical company specializing in allergy vaccines announces today that 137,491,788 of its ordinary shares were transferred on 28 September 2010 by Azure Ventures Limited to Yissum Holdings Limited a company controlled by members of the Weinstein family, including Mr Alejandro Weinstein Jr, a non-executive director of the Company. Notification of the transfer was received by the Company on 4 October 2010. There has been no change in the aggregate beneficial holding of shares in the Company by the Weinstein family.

 

 

The Karjiang Pharma Trust, of which the Weinstein family, including Mr Alejandro Weinstein Jr., are beneficiaries, continues to hold 3,076,499 shares in the Company, through Azure Ventures Limited. As a result of the transfer the percentage of voting rights controlled by the Karjiang Pharma Trust has fallen from 45.23 per cent. to below 3 per cent.

 

Yissum Holdings Limited, a company which is controlled by the Weinstein family, including Mr Alejandro Weinstein Jr., now holds 137,491,788 shares in the Company, representing 44.24 per cent. of the Company's total voting rights.

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Christopher Golden

www.nomuracode.com

 

Financial Dynamics

+44 (0) 207 831 3113

Ben Brewerton/ Susan Quigley

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGIBDGXSGBGGS
Date   Source Headline
26th Sep 201611:59 amRNSDirector/PDMR Shareholding
26th Sep 201610:46 amRNSHardman Research: Performance drives market share
26th Sep 20167:00 amRNSAllergy Therapeutics Preliminary Results
20th Sep 20164:58 pmRNSIssue of equity in respect of exercise of options
5th Sep 20167:00 amRNSNotice of Preliminary Results
13th Jul 20167:00 amRNSTrading Update
8th Jul 20167:00 amRNSResults of mite immunotherapy Acarovac PlusT
27th Jun 20167:00 amRNSFindings from mEEC dose range finding study G204
13th Jun 20167:00 amRNSAllergy hosts Satellite Symposium at EAACI
10th Jun 20167:00 amRNSAppointment of Finance Director
9th May 20167:00 amRNSPositive Phase II Data
23rd Mar 20169:02 amRNSIssue of equity in respect of options exercise
17th Mar 20167:00 amRNSBoard Change
11th Mar 20164:36 pmRNSGrant of Options under Long Term Incentive Plan
8th Mar 20167:00 amRNSInterim Results for the six months ended 31/12/15
24th Feb 20167:30 amRNSHardman & Co Research Report: Development Progress
23rd Feb 20167:00 amRNSNotice of Interim Results
18th Feb 20167:00 amRNSPatient enrolment completed in US Phase IIb study
13th Jan 20167:00 amRNSTrading Update
7th Dec 20157:00 amRNSUS Phase II study for GrassMATAMPL initiated
2nd Dec 20153:47 pmRNSHolding(s) in Company
30th Nov 20157:00 amRNSPQBirch204 Phase II study update
27th Nov 20153:21 pmRNSHolding(s) in Company
25th Nov 20156:06 pmRNSGrant of Options under Long Term Incentive Plan
18th Nov 201512:23 pmRNSResult of AGM
17th Nov 201512:51 pmRNSResults of Placing
17th Nov 20157:01 amRNSProposed placing to raise up to £12 million
17th Nov 20157:00 amRNSTrading Update
4th Nov 20157:00 amRNSWorld Vaccine Congress Presentation
21st Oct 20152:48 pmRNSHardman & Co issues research report
16th Oct 20157:00 amRNSAnnual Report and Accounts
21st Sep 20157:00 amRNSFinal Results
1st Sep 20157:04 amRNSFirst patient recruited in PQ Birch dose study
10th Aug 20157:00 amRNSKey paper published in the World Allergy Journal
27th Jul 20157:00 amRNSDirector Share Dealings
23rd Jul 20157:00 amRNSNotice of Results and Trading Update
6th Jul 20157:00 amRNSPositive Dust Mite Study Results
2nd Jul 20157:00 amRNSCompany to Host Key Allergy Conference
25th Jun 20157:00 amRNSCompany to resume US clinical programme
5th Jun 201510:59 amRNSAcquisition of Alerpharma S.A.
9th Apr 20155:51 pmRNSHolding(s) in Company
8th Apr 20153:47 pmRNSHolding(s) in Company
1st Apr 20153:20 pmRNSHolding(s) in Company
30th Mar 201511:27 amRNSResult of General Meeting and Issue of Equity
10th Mar 20157:03 amRNSIssue of Equity
2nd Mar 20157:00 amRNSHalf Yearly Report
30th Jan 20153:58 pmRNSHolding(s) in Company
12th Jan 20157:00 amRNSTrading Update
16th Dec 20142:00 pmRNSChange of Adviser
19th Nov 20141:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.